Patients with CADM and anti-MDA5 antibodies can develop a syndrome comprising rapidly progressive ILD and refractory respiratory insufficiency similar to that generated by SARS-CoV-2. The gene discussed is IFIH1; the disease is clinically amyopathic dermatomyositis.